C83.15
Mantle cell lymphoma, lymph nodes of inguinal region and lower limb
Clinical Classification Guidelines
Medical Intelligence & Overview
Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma that originates from B-cells in the mantle zone of lymphatic tissue. The specific coding C83.15 pertains to cases where this lymphoma affects lymph nodes in the inguinal region — located in the groin — and the lower limbs. This form of lymphoma can present unique challenges due to its specific location and the way it progresses, requiring targeted diagnostic and therapeutic approaches.
Causes & Symptoms
Clinical Causes: Genetic mutations in B-cells, especially involving the overexpression of the cyclin D1 gene due to chromosomal translocation t(11;14) Age: Most cases are diagnosed in individuals over age 60 Gender: Males are more frequently affected than females History of autoimmune diseases or previous radiation therapy Family history of lymphoma or other cancers Environmental exposures: Certain chemicals and pesticides have been studied, but definitive links are lacking
Key Symptoms: Enlarged lymph nodes in the groin or along the thighs Swelling or a noticeable lump in the groin or lower limbs Persistent or unexplained weight loss Fever and night sweats Fatigue and weakness Pain or discomfort in the affected areas Itching or skin lesions, if skin involvement occurs In advanced cases, symptoms related to gastrointestinal or bone marrow infiltration
Diagnostic & Treatment
Diagnosis Path: Physical examination focusing on lymph node regions, especially inguinal and lower limb areas Imaging studies such as CT scans, PET scans, or MRI to determine the extent of lymph node involvement and detect possible spread Blood tests to evaluate blood counts and overall health Lymph node biopsy: Removing a tissue sample for microscopic examination to identify abnormal B-cells characteristic of MCL Immunohistochemistry: Testing biopsy samples for markers like cyclin D1 that are typical of mantle cell lymphoma Molecular testing or cytogenetics to identify chromosomal translocations or mutations Bone marrow biopsy may be necessary if systemic involvement is suspected
Treatment Protocols: Chemotherapy: Using drugs to target rapidly dividing cancer cells, often combined with immunotherapy agents Immunotherapy: Monoclonal antibodies like rituximab target specific proteins on lymphoma cells Targeted therapy: Drugs such as BTK inhibitors (e.g., ibrutinib) that interfere with B-cell signaling pathways Radiation therapy: May be used in localized cases to reduce tumor size or control symptoms Stem cell transplant: Used in certain cases to consolidate remission after initial therapy Clinical trials: Exploring new therapies and combinations for better outcomes
Clinical Advice & FAQs
Billing Guidance
Is C83.15 a billable ICD-10 code?
Yes, C83.15 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C83.15?
Clinical documentation must specify the nature of Mantle cell lymphoma, lymph nodes of inguinal region and lower limb and any associated comorbidities for accurate reporting.
Cite this Clinical Reference